← Back to Screener
Opus Genetics, Inc. Common Stock (IRD)
Price$5.54
Favorite Metrics
Price vs S&P 500 (26W)184.62%
Price vs S&P 500 (4W)21.49%
Market Capitalization$409.11M
All Metrics
Book Value / Share (Quarterly)$0.22
P/TBV (Annual)20.69x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-29.11%
Cash Flow / Share (Quarterly)$-0.50
Price vs S&P 500 (YTD)181.93%
Net Profit Margin (TTM)-349.33%
EPS (TTM)$-0.81
10-Day Avg Trading Volume0.69M
EPS Excl Extra (TTM)$-0.81
EPS (Annual)$-0.80
ROI (Annual)-300.97%
Gross Margin (Annual)87.50%
Net Profit Margin (5Y Avg)-2097.75%
Cash / Share (Quarterly)$0.65
Revenue Growth QoQ (YoY)-10.16%
ROA (Last FY)-98.70%
Revenue Growth TTM (YoY)29.15%
EBITD / Share (TTM)$-0.82
ROE (5Y Avg)-156.92%
Operating Margin (TTM)-271.90%
Cash Flow / Share (Annual)$-0.50
P/B Ratio26.66x
P/B Ratio (Quarterly)9.03x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)25.72x
Net Interest Coverage (TTM)-32.83x
ROA (TTM)-114.53%
EV / EBITDA (TTM)12.03x
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)6.43x
Quick Ratio (Quarterly)6.20x
3-Month Avg Trading Volume0.84M
52-Week Price Return682.21%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$38.85
P/S Ratio (Annual)28.82x
Asset Turnover (Annual)0.28x
52-Week High$5.81
Operating Margin (5Y Avg)-938.76%
EPS Excl Extra (Annual)$-0.80
26-Week Price Return193.37%
Quick Ratio (Annual)6.20x
13-Week Price Return164.98%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)6.43x
Enterprise Value$365.145
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-53.37%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-349.33%
Cash / Share (Annual)$0.65
3-Month Return Std Dev85.37%
Net Income / Employee (TTM)$-2
ROE (Last FY)-323.11%
Net Interest Coverage (Annual)-262.39x
EPS Basic Excl Extra (Annual)$-0.80
Receivables Turnover (TTM)3.18x
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-0.81
Receivables Turnover (Annual)3.18x
ROI (TTM)-301.00%
P/S Ratio (TTM)28.82x
Pretax Margin (5Y Avg)-2097.58%
Revenue / Share (Annual)$0.23
Tangible BV / Share (Annual)$20.08
Price vs S&P 500 (52W)647.11%
Year-to-Date Return186.07%
5-Day Price Return3.23%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-90.83%
Net Profit Margin (Annual)-349.33%
Month-to-Date Return26.37%
EBITD / Share (Annual)$-0.77
Operating Margin (Annual)-271.90%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)-151.28%
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-0.81
P/TBV (Quarterly)10.58x
P/B Ratio (Annual)9.03x
Pretax Margin (TTM)-349.33%
Book Value / Share (Annual)$0.22
Price vs S&P 500 (13W)162.11%
Beta0.71x
P/FCF (Annual)28.59x
Revenue / Share (TTM)$0.18
ROE (TTM)-316.35%
52-Week Low$0.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.13
4.13
4.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. Common Stock | 28.82x | 29.15% | — | — | $5.54 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases and other retinal and refractive disorders. Its pipeline includes AAV-based gene therapies for bestrophinopathy, Leber congenital amaurosis, and retinitis pigmentosa, along with small-molecule and ophthalmic solutions for diabetic retinopathy and pupil dysfunction.